The ADXS chart settings shown below allow you to select time intervals of 1 min, 30 mins, an hour or by day - week - month. There is also the ability to change the ADXS chart style to candles, hollow candles, bars, lines or add various indicators. You can even add a symbol and compare history.
The ADXS stock resources shown below were gathered to cut back on time by allowing you to visit multiple sites at once. For your convenience each link clicked will open in a window. In addition to the individual links there is a button at the bottom that will allow you to open all the links at the same time. Note opening all links at once may not work with all browsers. Some browsers block multiple windows, to resolve this please allow that site to use pop-ups.
View ADXS Detailed Price Forecast - CNN Money | View ADXS Detailed Summary - Google Finance | ||
View ADXS Detailed Summary - Yahoo! Finance | View ADXS Stock Research & Analysis - Zacks.com |
View ADXS Trends & Analysis - Trade-Ideas | View ADXS Major Holders - Barrons | ||
View ADXS Call Transcripts - NASDAQ | View ADXS Breaking News & Analysis - Seeking Alpha | ||
View ADXS Annual Report - CompanySpotlight.com | View ADXS OTC Short Report - OTCShortReport.com | ||
View ADXS Fundamentals - TradeKing | View ADXS SEC Filings - Bar Chart | ||
View Historical Prices for ADXS - The WSJ | View Performance/Total Return for ADXS - Morningstar | ||
View the Analyst Estimates for ADXS - MarketWatch | View the Earnings History for ADXS - CNBC | ||
View the ADXS Earnings - StockMarketWatch | View ADXS Buy or Sell Recommendations - MacroAxis | ||
View the ADXS Bullish Patterns - American Bulls | View ADXS Short Pain Metrics - ShortPainBot.com |
View ADXS Stock Mentions - StockTwits | View ADXS Stock Mentions - PennyStockTweets | ||
View ADXS Stock Mentions - Twitter | View ADXS Investment Forum News - Investor Hub | ||
View ADXS Stock Mentions - Yahoo! Message Board | View ADXS Stock Mentions - Seeking Alpha |
View Insider Transactions for ADXS - SECform4.com | View Insider Transactions for ADXS - Insider Cow | ||
View ADXS Major Holdings Summary - CNBC | View Insider Disclosure for ADXS - OTC Markets | ||
View Insider Transactions for ADXS - Yahoo! Finance | View Institutional Holdings for ADXS - NASDAQ |
View ADXS Stock Insight & Charts - FinViz.com | View ADXS Investment Charts - StockCharts.com | ||
View ADXS Stock Overview & Charts - BarChart | View ADXS User Generated Charts - Trading View |
Ayala Pharmaceuticals Announces Completion of Sale of AL102 to Immunome
Posted on Tuesday March 26, 2024
MONMOUTH JUNCTION, N.J., March 26, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced the completion of the previously announced sale of AL102, and related drug candidate AL101, to Immunome, Inc. (Nasdaq: IMNM). As per the terms of the sale, Ayala received from Immunome $20 million in cash and 2,175,489 shares of Immunome common stock, and Immunome assumed specified liabilities related to AL102. Ayala may also receive up to an a
Ayala Pharmaceuticals Announces Completion of Enrollment in Phase 3 RINGSIDE Study Evaluating AL102 in Desmoid Tumors
Posted on Tuesday February 20, 2024
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that patient enrollment has been completed in the Phase 3 RINGSIDE study evaluating AL102 in desmoid tumors. A total of 156 patients were enrolled. ”Completion of enrollment in RINGSIDE represents a significant milestone in the development of AL102,” said Kenneth Berlin, President and Chief Executive Officer of Ayala. “There
Immunome to Acquire AL102, a Phase 3 Asset for the Treatment of Desmoid Tumors, From Ayala Pharmaceuticals
Posted on Tuesday February 06, 2024
BOTHELL, Wash. & MONMOUTH JUNCTION, N.J., February 06, 2024--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that it entered into a definitive asset purchase agreement with Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, to acquire AL102 and related drug candidate AL101 from Ayala. Based on the terms of the agreement, Immunome will pay Ayala $20 million in cash
Ayala Pharmaceuticals Announces AL102 Receives Orphan Drug Designation for Desmoid Tumors
Posted on Monday November 06, 2023
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a clinical-stage oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to AL102, a Gamma Secretase Inhibitor (GSI), for the treatment of desmoid tumors (DT). AL102 is an investigational small molecule GSI, currently being evaluated in the Phase 3 RINGSIDE study in DT. Orphan drug designation is granted by the FD